The new point of care, easy-to-use, rapid microfluidic immunoassay has been designed to quickly quantify the CRP levels in whole blood and plasma.
It uses a finger-prick blood sample and provides results in four minutes on the portable LumiraDx Platform.
The measurement of CRP levels provides information to detect and assess infection, inflammation disorders, tissue injury, and related illnesses.
LumiraDx stated that the CRP test can be used in several clinical settings such as GPs, OPDs, ICUs, paediatric departments, EDs, as well as other clinical care settings across the country.
This helps minimise unnecessary prescription of antibiotics in primary care that leads to antimicrobial resistance.
LumiraDx India general manager Yogesh Singh said: “India, one of the world’s most populated nations has greatly been impacted by antimicrobial resistance.
“The availability of the LumiraDx CRP Point of Care Antigen Test can help to ensure that antibiotics are only given to patients who will benefit from them.”
Studies demonstrated that the new point of care CRP testing reduces 23% to 36% of antibiotic prescribing for respiratory tract infections (RTI), as well as 22% for COPD.
LumiraDx chief innovation officer Dr Nigel Lindner said: “Global emergence of antimicrobial resistant pathogens presents an urgent need for practical and innovative solutions to control and prevent the use of antibiotics, especially where unnecessary prescriptions, self-medication and poor compliance persist.
“Ensuring doctors’ access to crucial actionable CRP test results in care settings is a sustainable way to future-proof our system against antibiotic resistance.”
This June, LumiraDx received the CE mark for SARS-CoV-2 & Flu A/B RNA STAR Complete and Dual-Target SARS-CoV-2 STAR Complete multiplex tests.